Atuação do farmacêutico frente ao uso indiscriminado de semaglutida para fins de emagrecimento
Revista ft · 31.10.2026 · 30 (163) · 01-16
DOI: 10.69849/5c2qw008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista ft, online erschienen am 31.10.2026. Verfasst von Renata Gabrielle Bezerra de Almeida und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Obesity is a chronic, multifactorial disease associated with the development of various comorbidities, requiring continuous monitoring and a multiprofessional approach. In this context, semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has gained prominence due to its effects on body weight reduction. However, the growing use of semaglutide for weight loss, particularly when driven by social media publicity, may encourage inappropriate use, self-medication, and use without professional supervision, thereby increasing risks associated with pharmacotherapy. Given this scenario, the present study aimed to analyze the pharmacist's role regarding the indiscriminate use of semaglutide for weight loss, emphasizing the promotion of rational use and patient safety. This study is a qualitative, descriptive literature review conducted through the survey and analysis of scientific publications available in the SciELO, PubMed/MEDLINE, and LILACS databases. Studies published between 2021 and 2025 in Portuguese, English, and Spanish were considered; they were required to be available in full text and related to semaglutide, weight loss, adverse effects, indiscriminate or off-label use, and the pharmacist's role. Following the application of inclusion and exclusion criteria and the analysis of titles, abstracts, and full texts, 10 studies were selected for the final sample. The results demonstrated that semaglutide is effective for reducing body weight; however, adverse effects can occur even when it is used appropriately, and weight may be regained after treatment discontinuation. The studies also discussed off-label use of certain formulations for aesthetic purposes and the risks of use without professional supervision. The studies also highlighted the importance of professional guidance, pharmacotherapeutic monitoring, the identification of potential risks, and the promotion of the rational use of the medication. In this context, the pharmacist plays a significant role in health education, guided dispensing, patient monitoring, the identification of medication-related problems, and pharmacovigilance activities. It is concluded that the pharmacist's involvement is a crucial component in promoting rational use and patient safety amidst the indiscriminate use of semaglutide for weight loss purposes.
Zitieren
APA
Almeida, R. G. B. D., & Borges, F. D. S. Q. (2026). Atuação do farmacêutico frente ao uso indiscriminado de semaglutida para fins de emagrecimento. Revista ft, 30(163), 01-16. https://doi.org/10.69849/5c2qw008
Vancouver
Almeida RGBD, Borges FDSQ. Atuação do farmacêutico frente ao uso indiscriminado de semaglutida para fins de emagrecimento. Revista ft. 2026;30(163):01-16. doi:10.69849/5c2qw008
BibTeX
@article{Almeida2026,
author = {Almeida, Renata Gabrielle Bezerra de and Borges, Faldrécya de Sousa Queiroz},
title = {Atuação do farmacêutico frente ao uso indiscriminado de semaglutida para fins de emagrecimento},
journal = {Revista ft},
year = {2026},
volume = {30},
number = {163},
pages = {01--16},
doi = {10.69849/5c2qw008}
}
EUVIMED